Aurora A kinase activates YAP signaling in triple-negative breast cancer

被引：0
作者：
S-S Chang
H Yamaguchi
W Xia
S-O Lim
Y Khotskaya
Y Wu
W-C Chang
Q Liu
M-C Hung
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Molecular and Cellular Oncology
[2] Cancer Biology Program,Department of Breast Medical Oncology
[3] The University of Texas Graduate School of Biomedical Sciences at Houston,Department of Biotechnology
[4] Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy,undefined
[5] The University of Texas MD Anderson Cancer Center,undefined
[6] The University of Texas MD Anderson Cancer Center,undefined
[7] Center for Molecular Medicine and Graduate Institute of Cancer Biology,undefined
[8] China Medical University,undefined
[9] Sun Yat-Sen University Cancer Center,undefined
[10] State Key Laboratory of Oncology in South China,undefined
[11] Collaborative Innovation Center of Cancer Medicine,undefined
[12] Institute of Cancer Stem Cell,undefined
[13] First Affiliated Hospital Collaborative Innovation Center of Oncology,undefined
[14] Dalian Medical University,undefined
[15] Asia University,undefined
来源：
Oncogene | 2017年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The Yes-associated protein (YAP) is an effector that transduces the output of the Hippo pathway to transcriptional modulation. Considering the role of YAP in cancers, this protein has emerged as a key node in malignancy development. In this study, we determined that Aurora A kinase acts as a positive regulator for YAP-mediated transcriptional machinery. Specifically, YAP associates with Aurora A predominantly in the nucleus. Activation of Aurora A can impinge on YAP activity through direct phosphorylation. Moreover, aberrant expression of YAP and Aurora A signaling is highly correlated with triple-negative breast cancer (TNBC). We herein provide evidence to establish the functional relevance of this newly discovered regulatory axis in TNBC.
引用
收藏
页码：1265 / 1275
页数：10
相关论文
共 297 条
  • [1] Johnson R(2014)The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment Nat Rev Drug Discov 13 63-79
  • [2] Halder G(2015)The emerging roles of YAP and TAZ in cancer Nat Rev Cancer 15 73-79
  • [3] Moroishi T(2015)The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer Clin Cancer Res 21 2580-2590
  • [4] Hansen CG(2011)The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells Cell 147 759-772
  • [5] Guan KL(2012)The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain Proc Natl Acad Sci USA 109 E2441-E2450
  • [6] Song S(2014)Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis EMBO J 33 468-481
  • [7] Honjo S(2014)YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a Hippo-independent pathway Cancer Res 74 4493-4503
  • [8] Jin J(2007)YAP1 increases organ size and expands undifferentiated progenitor cells Curr Biol 17 2054-2060
  • [9] Chang SS(2007)Elucidation of a universal size-control mechanism in Drosophila and mammals Cell 130 1120-1133
  • [10] Scott AW(2014)Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer Cell 158 185-197
12345678910